menu
    • menu
    [{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"Nav1.5 Sodium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Correvio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Correvio Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Hong Kong Teson Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tirofiban","moa":"Integrin-alpha 2b\/beta 3","graph1":"Hematology","graph2":"Approved FDF","graph3":"Correvio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Correvio Pharma \/ Hong Kong Teson Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Correvio Pharma \/ Hong Kong Teson Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Correvio Pharma

    Menu

    Correvio Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Correvio Pharma

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Correvio Pharma

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Hong Kong Teson Pharma

                            Deal Size : $3.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Correvio Partners with Hong Kong Teson Pharma Limited

                            Details :

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $3.0 million

                            October 03, 2020

                            Lead Product(s) : Tirofiban

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Hong Kong Teson Pharma

                            Deal Size : $3.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Correvio Pharma

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Correvio Pharma

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vernakalant Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Advanz Pharma

                            Deal Size : $76.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp

                            Details :

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $76.0 million

                            May 27, 2020

                            Lead Product(s) : Vernakalant Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Advanz Pharma

                            Deal Size : $76.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth